Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain

BACKGROUND Sporadic arteriovenous malformations of the brain, which are morphologically abnormal connections between arteries and veins in the brain vasculature, are a leading cause of hemorrhagic stroke in young adults and children. The genetic cause of this rare focal disorder is unknown. METHODS We analyzed tissue and blood samples from patients with arteriovenous malformations of the brain to detect somatic mutations. We performed exome DNA sequencing of tissue samples of arteriovenous malformations of the brain from 26 patients in the main study group and of paired blood samples from 17 of those patients. To confirm our findings, we performed droplet digital polymerase‐chain‐reaction (PCR) analysis of tissue samples from 39 patients in the main study group (21 with matching blood samples) and from 33 patients in an independent validation group. We interrogated the downstream signaling pathways, changes in gene expression, and cellular phenotype that were induced by activating KRAS mutations, which we had discovered in tissue samples. RESULTS We detected somatic activating KRAS mutations in tissue samples from 45 of the 72 patients and in none of the 21 paired blood samples. In endothelial cell–enriched cultures derived from arteriovenous malformations of the brain, we detected KRAS mutations and observed that expression of mutant KRAS (KRASG12V) in endothelial cells in vitro induced increased ERK (extracellular signal‐regulated kinase) activity, increased expression of genes related to angiogenesis and Notch signaling, and enhanced migratory behavior. These processes were reversed by inhibition of MAPK (mitogen‐activated protein kinase)–ERK signaling. CONCLUSIONS We identified activating KRAS mutations in the majority of tissue samples of arteriovenous malformations of the brain that we analyzed. We propose that these malformations develop as a result of KRAS‐induced activation of the MAPK–ERK signaling pathway in brain endothelial cells. (Funded by the Swiss Cancer League and others.)

[1]  Yajie Wang,et al.  Receptors of the Notch signaling pathway are associated with hemorrhage of brain arteriovenous malformations. , 2014, Molecular medicine reports.

[2]  A. Cuadrado,et al.  Mechanisms and functions of p38 MAPK signalling. , 2010, The Biochemical journal.

[3]  Tyson N. Kim,et al.  Notch4 Normalization Reduces Blood Vessel Size in Arteriovenous Malformations , 2012, Science Translational Medicine.

[4]  L. Wood,et al.  Cancer‐Associated Mutations in Endometriosis without Cancer , 2017, The New England journal of medicine.

[5]  I. Awad,et al.  Expression of Endothelial Cell Angiogenesis Receptors in Human Cerebrovascular Malformations , 2001, Neurosurgery.

[6]  G. Pavesi,et al.  Endothelial cells from human cerebral aneurysm and arteriovenous malformation release ET-1 in response to vessel rupture. , 2006, International journal of molecular medicine.

[7]  S. Cagnol,et al.  Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition , 2013, Oncogene.

[8]  W. Chung,et al.  Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling , 2017, Circulation.

[9]  D. Bar-Sagi,et al.  A Lipid-Anchored Grb2-Binding Protein That Links FGF-Receptor Activation to the Ras/MAPK Signaling Pathway , 1997, Cell.

[10]  J. Mulliken,et al.  Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation. , 2017, American journal of human genetics.

[11]  J. Mulliken,et al.  Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast‐flow vascular anomalies are caused by RASA1 mutations , 2008, Human mutation.

[12]  M. Lawton,et al.  Notch-1 signalling is activated in brain arteriovenous malformations in humans. , 2009, Brain : a journal of neurology.

[13]  A. Bollen,et al.  Endothelial Notch signaling is upregulated in human brain arteriovenous malformations and a mouse model of the disease , 2009, Laboratory Investigation.

[14]  Tyson N. Kim,et al.  Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice , 2008, Proceedings of the National Academy of Sciences.

[15]  A. Rustgi,et al.  A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4) , 2004, The Lancet.

[16]  Peter J Park,et al.  A dynamic H3K27ac signature identifies VEGFA-stimulated endothelial enhancers and requires EP300 activity , 2013, Genome research.

[17]  J. Mulliken,et al.  Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma. , 2016, American journal of human genetics.

[18]  S. Lewis.  Prevalence of adults with brain arteriovenous malformations , 2002 .

[19]  Joshua D. Wythe,et al.  The molecular regulation of arteriovenous specification and maintenance , 2015, Developmental dynamics : an official publication of the American Association of Anatomists.

[20]  M. Hellström,et al.  Notch as a hub for signaling in angiogenesis. , 2013, Experimental cell research.

[21]  C. Warlow,et al.  A systematic review of the frequency and prognosis of arteriovenous malformations of the brain in adults. , 2001, Brain : a journal of neurology.

[22]  K. Pumiglia,et al.  Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation* , 2001, The Journal of Biological Chemistry.

[23]  D. W. Johnson,et al.  Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.

[24]  D. W. Johnson,et al.  Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2 , 1996, Nature Genetics.

[25]  Frank McCormick,et al.  RAS Proteins and Their Regulators in Human Disease , 2017, Cell.

[26]  N. Kamitaki,et al.  Endothelial Cells from Capillary Malformations Are Enriched for Somatic GNAQ Mutations , 2016, Plastic and reconstructive surgery.

[27]  Alexander Dobrovic,et al.  Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase , 2012, Oncotarget.

[28]  D. Wiebers,et al.  Incidence and prevalence of intracranial vascular malformations in Olmsted County, Minnesota, 1965 to 1992 , 1996, Neurology.

[29]  J. Mulliken,et al.  A somatic MAP3K3 mutation is associated with verrucous venous malformation. , 2015, American journal of human genetics.

[30]  A. Adjei,et al.  The clinical development of MEK inhibitors , 2014, Nature Reviews Clinical Oncology.

[31]  Tyson N. Kim,et al.  Constitutively active Notch4 receptor elicits brain arteriovenous malformations through enlargement of capillary-like vessels , 2014, Proceedings of the National Academy of Sciences.

[32]  R. Helaers,et al.  Somatic Activating PIK3CA Mutations Cause Venous Malformation. , 2015, American journal of human genetics.

[33]  H. Dressman,et al.  Gene Microarray Analysis of Human Brain Arteriovenous Malformations , 2004, Neurosurgery.

[34]  Michael J. Parsons,et al.  Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey , 2014, Oncogene.

[35]  L. Ferrarini,et al.  EndMT contributes to the onset and progression of cerebral cavernous malformations , 2013, Nature.